Transcriptome, Methylome and Genomic Variations Analysis of Ectopic Thyroid Glands

Rasha Abu-Khudir1,2, Jean Paquette1, Anne Lefort3, Frederick Libert3, Jean-Pierre Chanoine4, Gilbert Vassart3, Johnny Deladoey1,2*

1 Department of Pediatrics, Endocrinology Service and Research Center, CHU Sainte-Justine, University of Montreal, Montreal, Canada, 2 Department of Biochemistry, University of Montreal, Montreal, Canada, 3 IRIBHM, Free University of Brussels ULB, Brussels, Belgium, 4 Endocrinology and Diabetes Unit, Department of Pediatrics, BC Children’s Hospital, University of British Columbia, Vancouver, Canada

Abstract

Background: Congenital hypothyroidism from thyroid dysgenesis (CHTD) is predominantly a sporadic disease characterized by defects in the differentiation, migration or growth of thyroid tissue. Of these defects, incomplete migration resulting in ectopic thyroid tissue is the most common (up to 80%). Germinal mutations in the thyroid-related transcription factors NKX2.1, FOXE1, PAX-8, and NKX2.5 have been identified in only 3% of patients with sporadic CHTD. Moreover, a survey of monozygotic twins yielded a discordance rate of 92%, suggesting that somatic events, genetic or epigenetic, probably play an important role in the etiology of CHTD.

Methodology/Principal Findings: To assess the role of somatic genetic or epigenetic processes in CHTD, we analyzed gene expression, genome-wide methylation, and structural genome variations in normal versus ectopic thyroid tissue. In total, 1011 genes were more than two-fold induced or repressed. Expression array was validated by quantitative real-time RT-PCR for 100 genes. After correction for differences in thyroid activation state, 19 genes were exclusively associated with thyroid ectopy, among which genes involved in embryonic development (e.g. TXNIP) and in the Wnt pathway (e.g. SFRP2 and FRZB) were observed. None of the thyroid related transcription factors (FOXE1, HHEX, NKX2.1, NKX2.5) showed decreased expression, whereas PAX8 expression was associated with thyroid activation state. Finally, the expression profile was independent of promoter and CpG island methylation and of structural genome variations.

Conclusions/Significance: This is the first integrative molecular analysis of ectopic thyroid tissue. Ectopic thyroids show a differential gene expression compared to that of normal thyroids, although molecular basis could not be defined. Replication of this pilot study on a larger cohort could lead to unraveling the elusive cause of defective thyroid migration during embryogenesis.

Citation: Abu-Khudir R, Paquette J, Lefort F, Chanoine J-P, et al. (2010) Transcriptome, Methylome and Genomic Variations Analysis of Ectopic Thyroid Glands. PLoS ONE 5(10): e13420. doi:10.1371/journal.pone.0013420

Editor: Amanda Ewart Toland, Ohio State University Medical Center, United States of America

Received March 12, 2010; Accepted September 17, 2010; Published October 15, 2010

Copyright: © 2010 Abu-Khudir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a joint scholarship from the Egyptian Ministry of Higher Education and University of Montreal (to R.A.K.); by a research junior 1 scholarship of the Fonds de Recherche en Santé du Québec (FRSQ) and by a fellowship from the Canadian Child Health Clinician Scientist Program (CCHCSP) (to J.D.); by the Belgian Fonds de la Recherche Scientifique Médicale (FRSM) and Fonds ERASME (to F.L. and G.V.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: johnny.deladoey@umontreal.ca

† These authors contributed equally to this work.

Introduction

Permanent primary hypothyroidism is the most common congenital endocrine disorder. In up to 85% of cases, it results from thyroid dysgenesis, a condition comprised of defects in the differentiation, migration or growth of thyroid tissue. Of these defects, incomplete migration resulting in ectopic thyroid tissue (sub-lingual thyroid) is the most common (up to 80%). The etiological diagnosis is established through thyroid scintigraphy [1]. Ectopic thyroids are smaller (i.e. they lack the lateral lobes that are characteristic of orthotopic thyroids) but are otherwise normal (i.e. they have a normal follicular architecture and their capacity to trap and organize iodine and to produce thyroid hormones and thyroglobulin is intrinsically normal [2,3,4,5]). This suggests that the hypothyroidism of subjects with thyroid ectopy is due to a smaller amount of tissue (hypoplasia), which is a consequence of the migration defect, and not to defects in differentiation or in histological organization of the thyroid follicular cells.

Congenital hypothyroidism from thyroid dysgenesis (CHTD) is a heterogeneous disease, which exists in familial (2%) and non-familial (sporadic, 98%) forms [6]. Moreover, the results of a survey of monozygotic twins yielded a discordance rate of 92% [7], which together with the female predominance in CHTD [8] suggest that complex non-Mendelian mechanisms underlie this condition. On the other hand, environmental causes operating in utero are unlikely because: (i) no temporal or seasonal trends for CHTD have been observed [9] and (ii) MZ twins who are discordant for CHTD have similar birth weight (G. Van Vliet, personal communication). Germline mutations in thyroid related transcription factors NKX2.1, FOXE1, PAX-8, and NKX2.5...
have been identified in only 3% of patients with sporadic CHTD and linkage analysis excluded these genes in some multiplex families with CHTD, which is consistent with a complex genetic contribution [10]. Together these findings indicate the involvement of novel genes and pathways and underlines the importance of somatic epigenetic or genetic events [11].

Combining data of gene expression, DNA methylation and DNA copy number has led to the identification of novel genetic regulators of cancer [12,13]. Consistent with this approach, we aim to assess whether the transcriptome of ectopic thyroids is shaped by somatic genomic or epigenomic variations (Figure 1).

Results

Expression array identified 1011 genes that are more than two-fold induced or repressed

We used microarray analysis to compare the genome-wide RNA expression profile of normal (orthotopic; n = 1) versus abnormal (ectopic; n = 3) thyroid tissue. We identified 1833 differentially expressed genes, and a total of 1011 genes were induced (n = 522) or repressed (n = 489) more than two-fold. The forty genes with the highest differential expression are listed in Table 1. To validate the differential expression identified by microarray analysis, we performed quantitative real-time PCR (qRTPCR) of 100 genes in ectopic thyroids compared with the same commercial control (Ambion) used for the arrays; these 100 genes included highly differentially expressed genes and genes known to play a role in the thyroid function. Overall, there was a highly significant correlation between microarray and qRTPCR (Pearson correlation coefficient of 0.86, p<2.2 e-16)(Figure S1).

Functional annotation clustering of the 1011 differentially expressed genes showed enrichment for developmental processes

To assess whether the differentially expressed genes are related to development and organogenesis, we classified the 1011 differentially expressed genes into gene ontology (GO) groups using DAVID (Database for Annotation, Visualization and Integrated Discovery) with medium classification stringency. Table S1 shows the top three clusters for the 1011 differentially expressed genes (more than two-fold induced or repressed) with enrichment scores greater than 6 (i.e. p<1 E -06). Two of them are clusters of genes enriched for developmental processes. We next clustered separately the induced (n = 522) and the repressed (n = 489) genes using DAVID according to GO terms with high classification stringency. The top five clusters of induced genes with enrichment...
Table 1. Result of the expression array: the top twenty induced (upper panel) and top twenty repressed (lower panel) genes.

### TOP 20 induced genes

| Entrez Gene Name | Entrez Gene ID | Array a | q-value (%) b | qRTPCR RQ value c |
|------------------|---------------|---------|---------------|-------------------|
| LYZ              | 4069          | 5.99    | 0.0000        | 5.41              |
| FOSB             | 2354          | 5.48    | 0.0000        | 5.62              |
| IGJ              | 3512          | 5.44    | 0.0000        |                   |
| TRA@             | 6955          | 5.23    | 0.7897        |                   |
| PAX8             | 7849          | 4.68    | 0.0000        | 2.55              |
| CYBB             | 1536          | 4.62    | 0.0000        |                   |
| TRA@             | 6955          | 4.60    | 0.0000        |                   |
| HLA-DQA1         | 3117          | 4.56    | 0.0000        |                   |
| CECR1            | 51816         | 4.49    | 0.0000        |                   |
| HLA-DQB1         | 3119          | 4.41    | 0.0000        |                   |
| EGR1             | 1958          | 4.29    | 0.0000        |                   |
| RNASE6           | 6039          | 3.98    | 0.0000        |                   |
| SFRP2            | 6423          | 3.91    | 0.0000        | 4.74              |
| GPNMB            | 10457         | 3.87    | 0.0000        | 4.97              |
| PABPC1           | 26986         | 3.85    | 0.0000        |                   |
| MS4A6A           | 64231         | 3.84    | 0.0000        |                   |
| KLF4             | 9314          | 3.74    | 0.7897        |                   |
| HADHA            | 3030          | 3.61    | 0.7897        |                   |
| FOS              | 2353          | 3.61    | 0.0000        | 4.46              |
| IGHG4            | 3503          | 3.52    | 0.7897        |                   |

*Array mean ratio are expressed in log2.

**Q-values (i.e. minimal false discovery rate) are expressed in percent, all P-values are less than 0.001.

Validation with qRTPCR: RQ values are expressed in log2.

Bold characters indicate genes that are validated (13 of 14 tested) among these 40 genes.

doi:10.1371/journal.pone.0013420.t001

doi:10.1371/journal.pone.0013420.t001
scores greater than 5.5 (i.e., \( p < 0.5 \times 10^{-06} \)) show genes important for development, vasculogenesis, the extracellular matrix, immune system development and collagen whereas the top five clusters for repressed genes with enrichment scores greater than 4 (i.e., \( p < 1 \times 10^{-04} \)) show genes important for histone function, apoptosis, chromatin function, organelle and contractile functions (Table S2). Finally, the analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways with DAVID shows enrichment (\( p < 0.05 \)) for eight pathways, among which three are associated with cell-to-cell interaction (i.e., MAPK signaling pathway, focal adhesion and cell communication) (Figure 2).

**Additional validation against age-matched hyperfunctioning thyroid tissue selects 19 genes whose expression is related to thyroid ectopy and independent of thyroid activation state**

Level of activity (i.e., thyroid hormone production) and consequently expression of genes involved in thyroid hormone production is sensitive to thyroid stimulating hormone (TSH) [14,15]. CHTD patients have high TSH at diagnosis, after which the level of their TSH may vary depending on the compliance to the treatment; or the TSH is high for years in cases of delayed treatment, as in our case 1 (Table S3). To correct for differential TSH-dependent activation of thyroid tissue, we extended the qRT-PCR analysis for the 100 validated genes to three hyperfunctioning thyroid nodules (i.e., somatic activation of the TSH receptor) that had arisen in otherwise normal (orthotopic) thyroids. Of the 100 genes, 19 showed consistently induction or repression when compared to all types of controls (i.e., hyperfunctioning thyroid nodules and the commercial control) (Table 1). The 81 remaining genes showed divergent expression: i.e., they were either induced in ectopic thyroid when compared to the commercial control but repressed when compared to the three hyperfunctioning thyroid nodules or vice versa (Table S4), suggesting that the expression of those 81 genes was dependent of thyroid activation state.

**Pathway analysis of the 19 selected genes showed association with Wnt signalling pathway whereas the 81 excluded genes were enriched for thyroid hormonogenesis and function**

We then asked whether the use of two different types of control was able to exclude genes that are dependent on thyroid activation state and to identify genes associated exclusively with defective migration of the thyroid. To consider the level of expression (which is not possible with DAVID), we used the Ingenuity Pathways Analysis software for GO annotation and pathway analysis (Ingenuity® Systems, www.ingenuity.com). The 19 selected genes (Table 2) were enriched for the Wnt pathway, dendritic cell maturation pathway, and embryonic developmental functions (for each enrichment scores greater than 1.5; \( p < 0.02 \) and Benjamini-Hochberg multiple correction \( p < 0.05 \)). As expected, the 81 genes (Table S4) excluded because of divergent expression are enriched for thyroid hormonogenesis and function: thyroglobulin (TG), thyroid peroxidase (TPO), deiodinase type II (DIO2), deiodinase type 1 (DIO1), dual oxidase 2 (DUOX2), paired box gene 8 (PAX8), thyroid stimulating hormone receptor (TSHR) and thyroid hormone responsive SPOT14 homolog (THRSP) (i.e., for GO term endocrine system disorders, the enrichment score is 2; \( p < 0.01 \) and Benjamini-Hochberg multiple correction \( p < 0.01 \)). To control for tissue quality, we also analyzed 10 unregulated genes which are either well described thyroid-related transcription factors (FOXE1, HHEX, NKX2.1, NKX2.5) [16] or genes involved in the Wnt pathway (CTNNB1, GSK3B, CDH1, APC, AXIN1, AXIN2) [17]. CTNNB1 and CDH1 showed divergent expression; APC, AXIN1, AXIN2, FOXE1 and NKX2.1 showed increases of convergent expression; and NKX2.5 expression was massively increased when compared to orthotopic thyroids but only slightly increased when compared to the commercial control, which therefore might be considered as divergent. None of the thyroid related transcription factors (FOXE1, HHEX, NKX2.1, NKX2.5) showed decreased expression regardless of the control used (Table 3).

**Differential gene expression in ectopic thyroid is independent of methylation**

The next step was to assess whether somatic changes in DNA methylation play a role in dysregulation of gene expression in ectopic thyroid. Methylation profiling by methylated DNA immunoprecipitation (MeDIP) and MeDIP-chip was performed by hybridizing pairs of enriched methylated fraction (IP) and normal fraction (IN) of genomic DNA from our three ectopic thyroids and three controls (orthotopic hyperfunctioning thyroid nodules). The methylation profile was similar between the ectopic thyroids and three controls (orthotopic hyperfunctioning thyroid nodules) which therefore might be considered as divergent. None of the thyroid related transcription factors (FOXE1, HHEX, NKX2.1, NKX2.5) showed decreased expression regardless of the control used (Table 3).

**Figure 2. Expression array: gene pathway distribution in ectopic thyroid according to KEGG.** The pathways are classified according to the number of regulated genes (Heebo array results). P-values of Fisher’s exact test for each KEGG pathways are listed to the right of the boxes. Dark gray, induced genes; gray, repressed genes.

doi:10.1371/journal.pone.0013420.g002
Consequently, no correlation was found between the differential expression in ectopic thyroids and the global methylation profile.

Differential gene expression in ectopic thyroid is independent of thyroid-specific CNVs

To assess whether thyroid-specific (i.e. absent in matched leucocytes) CNVs shape gene expression in ectopic thyroids, we used array comparative genomic hybridization (aCGH) of the ectopic thyroid DNA with matched leucocytes. By analyzing data as described in Materials and Methods, we found four thyroid-specific CNVs (three validated by qPCR), which are reported variants as reported in the Database for Genomic Variants (http://projects.tcgca.ca/variation) (Table S5). No correlation was found between thyroid-specific CNVs and differentially expressed genes in ectopic thyroids.

| Entrez Gene Name | Entrez Gene ID | Array* | qRTPCR vs normal thyroid* | qRTPCR vs hot nodules* | Taq Man Assay ID for qRTPCR |
|------------------|----------------|--------|--------------------------|------------------------|-----------------------------|
| SFRP2            | 6423           | 3,91   | 4,74                     | 5,48                   | Hs00293258_m1               |
| TBX1             | 6899           | 1,52   | 3,21                     | 1,57                   | Hs00271949_m1               |
| GPNMB            | 10457          | 3,87   | 4,97                     | 1,45                   | Hs01095669_m1               |
| DUSP6            | 1848           | 1,98   | 3,09                     | 1,32                   | Hs01044001_m1               |
| FRZB             | 2487           | 0,83   | 1,83                     | 1,24                   | Hs00173503_m1               |
| COL1A1           | 1277           | 2,71   | 5,93                     | 1,10                   | Hs00164004_m1               |
| FGL2             | 10875          | 2,46   | 4,22                     | 1,00                   | Hs00173847_m1               |
| LYZ              | 4069           | 5,99   | 5,41                     | 0,94                   | Hs00426231_m1               |
| COL3A1           | 1281           | 3,39   | 5,12                     | 0,89                   | Hs00164103_m1               |
| TYROBP           | 7305           | 2,25   | 3,62                     | 0,76                   | Hs00182426_m1               |
| TNFAIP2          | 7127           | 3,45   | 4,63                     | 0,68                   | Hs00196800_m1               |
| BGN              | 633            | 1,09   | 3,14                     | 0,63                   | Hs00959143_m1               |
| PBX4             | 80714          | 1,83   | 3,67                     | 0,58                   | Hs00257935_m1               |
| PLCD1            | 55344          | 1,71   | 2,83                     | 0,58                   | Hs00383111_m1               |
| CPEB4            | 80315          | 1,28   | 2,6                      | 0,54                   | Hs00270923_s1               |
| MGRN1            | 23608          | 2,63   | 1,18                     | 0,53                   | Hs00831972_s1               |
| TXNIP            | 10628          | –2,81  | –1,78                    | –0,51                  | Hs01066900_g1               |
| ABCA13           | 154664         | –6,06  | –4,06                    | –0,71                  | Hs00541549_m1               |
| ENO3             | 2027           | –1,99  | –0,86                    | –1,15                  | Hs00266551_m1               |

*Array mean ratio and qRTPCR RQ are expressed in log2.

Table 3. Quantitative RTPCR for 10 controls.

| Entrez Gene Name | Entrez Gene ID | RQ of qRTPCR vs normal thyroid* | RQ of qRTPCR vs hot nodules* | Taq Man Assay ID for qRTPCR |
|------------------|----------------|--------------------------------|-----------------------------|-----------------------------|
| APC              | 324            | 2,31                           | 0,13                        | Hs01568269_m1               |
| AXIN1            | 8312           | 1,39                           | 0,2                         | Hs00394718_m1               |
| AXIN2            | 8313           | 2,05                           | 0,62                        | Hs01063168_m1               |
| CTNNB1           | 1499           | 1,35                           | –0,53                       | Hs00355045_m1               |
| CDH1             | 999            | 2,07                           | –0,35                       | Hs01070423_m1               |
| FOXE1            | 2304           | 2,58                           | 0,47                        | Hs00536731_s1               |
| GSK3B            | 2932           | 2,1                            | 0                           | Hs00275656_m1               |
| HHEX             | 3087           | 1,62                           | 0,05                        | Hs00242160_m1               |
| NKX2.1           | 16002          | 1,43                           | 0,36                        | Hs00163037_m1               |
| NKX2.5           | 1482           | 0,53                           | 6,93                        | Hs00231763_m1               |

*Array mean ratio and qRTPCR RQ are expressed in log2.

doi:10.1371/journal.pone.0013420.t003
Discussion

Generally, CHTD is sporadic and shows discordance between MZ twins [7]. Somatic genetic or epigenetic events might therefore have a role in the etiology of this condition. The objective of this study was to assess whether somatic molecular events account for the failure of migration of ectopic thyroids. Therefore, we conducted the first integrative analysis of transcriptome, DNA methylation and structural variants (CNV) in ectopic thyroids.

We found altered expression in genes and pathways that might play a significant role in abnormal thyroid development (e.g. Wnt signaling pathway). Interestingly, none of the thyroid related transcription factors (FOXE1, HHHEX, NKX2.1, NKX2.5) showed decreased expression, whereas PAX8 expression was associated with thyroid activation state. This is a direct indication that the expression of these known candidate genes is at least neutral in ectopic thyroid and is consistent with the observation that the coding sequences for FOXE1, NKX2.1 and PAX8 were normal in case #1 [5].

Four pathways identified by analysing the results of expression arrays (i.e. focal adhesion, antigen processing and presentation, cell communication, cell adhesion molecules and Type I diabetes) have been identified independently in hyperfunctioning thyroid nodules [18]. However, our results identify mostly induced genes in these pathways (Figure 1) whereas repression of this genes was observed in the aforementioned study [18]. To obtain, in ectopic thyroid, an opposite expression pattern when compared to that of orthotopic hyperfunctional thyroid (i.e. thyroid with somatic TSH receptor activating mutation) is plausible, but it underlines also the need to consider the differential activation of the TSH-receptor signaling pathways in our samples. Consequently, we have excluded 81 validated genes for which expression was associated with TSH-driven thyroidal activity.

The 19 selected genes whose expression was dependent on thyroid location (i.e. ectopy) were enriched for pathways involved in cellular movement (i.e. Wnt pathway and dendritic cell maturation pathway). This association has biological plausibility especially for the Wnt pathway. First, non-canonical Wnt pathway is crucial for cell migration [19] and development of organs of endodermal origin (e.g. intestine, lung, pancreas) [20]. There is indirect evidence for the involvement of the non-canonical Wnt pathway in the developing thyroid in mice [21], even though the canonical Wnt/beta-catenin pathway seems to be inactive during thyroid development in mice and humans [21,22]. Second, as Wnt signaling is implicated in development and cancer [23], to find an association between Wnt pathway and thyroid ectopy (i.e. failure of proper thyroid migration during development) makes biologically sense. Indeed, SFRPs have been associated with embryonic patterning [24], inhibition of medulloblastoma cell proliferation [25] and inhibition of glioma cell motility [26]. Inhibition of the Wnt pathway by Wnt3-a has also been shown to suppress tumor activity in thyroid carcinoma [27].

This study has several limitations. First, the expression profiles in tissue collected and analyzed postnatally may not reflect embryonic expression. Consequently, whether the differences we observed are causes or consequences of the ectopic location of the thyroid remains to be tested. Second, even though clusters of genes involved in histone and chromatin function have repressed expression in ectopic thyroids, we have not formally excluded a role of differential histone methylation or acetylation on differential gene expression in ectopic thyroids. Third, the arrays used for the CNVs and methylome analyses have their own limits in definition and genome coverage. Lastly, the sample number is small but our preliminary findings justify testing a larger number of samples.

This study identifies interesting candidate pathways that may play important roles in the migration of the embryonic thyroid and provides a prototype approach for the study of congenital disorders difficult to explain by classical genetics.

Methods

Ethic Statement

This study was approved by the Ethics Committee of the CHU Sainte-Justine (ERB number 94). All the parents gave written informed consent.

Patients and Tissue Collection

We obtained flash-frozen samples of ectopic thyroid tissue removed from 3 girls aged 8, 10 and 15 yr, because it caused local symptoms (i.e. dysphagia). For controls, we used (i) thyroid tissue from 2 girls (aged 15 and 16 yr) and 1 boy (aged 4 yr) who were operated for a single hyperfunctioning thyroid nodule that had arisen in an orthotopic thyroid and (ii) commercially available RNA from normal thyroid when appropriate (Table S3).

Functional clusters and pathways analysis

We submitted the 1011 differentially expressed genes into gene ontology (GO) groups using the DAVID database (http://david.abcc.ncifcrf.gov) for cluster analysis according to Gene Ontology (GO) terms with medium or high classification stringency. To provide a refined analysis, the 100 validated gene were analyzed through Ingenuity Pathways Analysis (IPA; http://www.ingenuity.com), a software that also considers the level of gene expression. With either DAVID or IPA, the proportion of each gene in the submitted list is compared with the one in the whole genome to compute the P value of the Fisher’s test, the enrichment scores (i.e. geometric mean of the inverse log of each P value) and the Benjamini-Hochberg multiple correction P value.

Expression Arrays

After surgical resection, the samples were immediately frozen in liquid nitrogen and stored at −70 Celsius until use. Total RNA was extracted as per manufacturer recommendations using the QIAZol kit (QIAGEN Inc., Ontario, Canada); RNA was DNase-treated to minimize DNA contamination. RNA quantity was measured by ND-1000 (Nanodrop, Wilmington, DE, USA). RNA quality was assessed by electropherograms on the Agilent 2100 Bioanalyzer. Microarray hybridization was performed on three different ectopic thyroids (two in duplicate, one in quadruplicate) and compared to RNA of thyroid tissue from a Caucasian female, age 68 y with gall bladder cancer (Ambion, #AM6872). Double-stranded cDNA was synthesized from 1 μg of total RNA, followed by production of antisense RNA containing the modified nucleotide 5-[(3-aminoallyl)-UTP using the Amino Allyl MessageAmpTM II aRNA Amplification kit (Ambion, Texas, USA). After labeling with Cy3 or Cy5 (GE Healthcare Bio-Sciences, New Jersey, USA), sample pairs were hybridized onto Human Exonic Evidence Based Oligonucleotide HEEBO slides (Stanford Functional Genomics Facility, CA, USA). The oligonucleotide set consists of 44544 70-mer probes that were designed using a transcriptome-based annotation of exonic structure for genomic loci. Hybridizations were replicated with dye swap. Slides were scanned using a Molecular Devices 4000B Laser scanner and expression levels were quantified using GenePix Pro 6.1 image analysis software (Axon Instruments, CA, USA). Image acquisitions were performed with automatic photomultiplier gains (PMT)
Methylation Profiling by Methylated DNA

Immunoprecipitation (MeDIP) and MeDIP-chip

The MeDIP-chip was performed using pairs of enriched methylated fraction (IP) and normal fraction (IN) of genomic DNA from our three ectopic thyroids and three controls (i.e. hyperfunctioning thyroid nodules). The methylated fraction of genomic DNA was enriched using the methylated DNA immunoprecipitation (MeDIP) assay [31] and interrogated on human Promoter plus Cpg Island Tiling Arrays with a ChIP design for Cpg islands and promoter regions (n = 28,226) from HG18 using 385,020 Probes selected from CGH probe bank with a median spacing of 101 bp (Roche NimbleGen, Madison, WI). Briefly, 4 μg MseI digested genomic DNA was immunoprecipitated with mononclonal mouse anti 5-methylcytidine antibody (New England Biolab, Pickering, Ontario and Abcam Inc.Cambridge, MA 02139). After washes and purification steps, immunoprecipitated material and a sample of input DNA were amplified using GenomePlex Complete Whole Genome Amplification (WGA) kit (Sigma-Aldrich, Saint Louis, Missouri 63103 USA). The resulting products (4 μg) were labeled, cohybridized and scanned by the NimbleGen Custom Service (Roche NimbleGen, Madison, WI). For each sample, NimbleScan detects peaks by searching for at least two probes above a P-value cutoff (−log10p) of 2 and peaks within 500 bp are merged (gff files on GEO web site). Then, peak data were analyzed to compare the methylation profile between ectopic thyroids and orthotopic thyroids using the Loess normalized log2 (ChIP/input) ratios with the one-way ANOVA tool of the Partek Genomics Suite (PGS) software. A FDR less than 0.1 was considered as significant. Full access to the primary array data is available on the GEO web site (http://www.ncbi.nlm.nih.gov/projects/geo/) under accession number GSE17581.

Array Comparative Genomic Hybridization and validation with quantitative real-time PCR

Array comparative genomic hybridization (aCGH) was performed using pairs of thyroid tissues and leucocytes from the three ectopic thyroids. We used the Nimblegen X1 HG18 whole genome CGH design (version 2). The 305,015 probes are distributed across the genome with a median spacing of 7073 bp. Probes are 60-mers, with a Tm target of 90 degrees. Labeling, hybridization, washing and scanning was performed by the NimbleGen Custom Service (Roche NimbleGen, Madison, WI). After normalization, the log2 (test/reference) signals were analyzed using a circular binary segmentation algorithm (segMNT) with the PGS Software to identify somatically acquired segmental copy number changes. To call a copy number change, segMNT required a segment to span a minimum of 5 consecutive probes with a p-value threshold of 0.001 and a signal to noise ratio of 0.3. Then, reported regions were set at segMNT log2 ratio below 0.3 or above 0.2 in all three samples with a p-value threshold of 0.01. Full access to the primary array data is available on the GEO web site (http://www.ncbi.nlm.nih.gov/projects/geo/) under accession number GSE17463. Validation of the aCGH with quantitative real-time PCR was performed with the TaqMan technology. Identified CNVs were validated using TaqMan Gene Copy Number Assays from ABI. Probes and primers have been selected with the public available software (http://www5.appliedbiosystems.com/tools/cnv/) and can be retrieved by using the assay ID reported in Table S5.

Supporting Information

Figure S1 Reliability of the HEEBO expression array was confirmed by calculating the Pearson correlation coefficient (r = 0.86; P<0.001) vs normal thyroid - Ambion, #AM6872) between microarray and qRT-PCR results. Results are expressed in log2 ratio.

Found at: doi:10.1371/journal.pone.0013420.s001 (0.01 MB PDF)

Table S1 The top three clusters for the 1011 differentially expressed genes (more than two-fold induced or repressed).

Found at: doi:10.1371/journal.pone.0013420.s002 (1.92 MB TIF)

Table S2 Clusters for the induced (n = 522) and repressed (n = 409) genes.
Table S3  Source of patients derived thyroid tissues.  
Found at: doi:10.1371/journal.pone.0013420.s003  (0.02 MB PDF)

Table S4  Validated genes (n = 81) with divergent expression in ectopic thyroid tissue (i.e. dependent on the activation state and independent of the localization of the thyroid tissue).  
Found at: doi:10.1371/journal.pone.0013420.s004  (0.02 MB PDF)

Table S5  Thyroid specific CNVs found in ectopic tissues.  
Found at: doi:10.1371/journal.pone.0013420.s005  (0.07 MB PDF)

References
1. Schoen EJ, Clapp W, To TT, Fimran BH (2004) The key role of newborn thyroid scintigraphy with isotopic iodide (123I) in defining and managing congenital hypothyroidism. Pediatrics 114: e685–e688.
2. Leger J, Taj A, Schlumberger M, Czernichow P (1988) Control of thyroid gland secretion in patients with ectopic thyroid gland. Pediatr Res 23: 266–269.
3. Gallo A, Leonetti F, Torri E, Manciocco V, Simonelli M, et al. (2001) Ectopic thyroid: a possible cause of severe dysphagia. Dysphagia 16: 220–223.
4. Toso A, Colombo S, Averso G, Aluffi P, Pia F (2009) Lingual thyroid causing dysphagia and dyspnoea. Case reports and review of the literature. Acta Otolaryngol Belg 19: 213–217.
5. Stoppane-Vachteri S, Lapointe A, Turpin S, Rydlewski C, Vassart G, et al. (2010) Ectopic Thyroid Gland causing Dysphonia: Imaging and Molecular Studies. J Clin Endocrinol Metab press.
6. Castanet M, Polak M, Bonnait-Pellie C, Lyonnnet S, Czernichow P, et al. (2001) Nineteen years of national screening for congenital hypothyroidism: familial cases with thyroid dysgenesis suggest the involvement of genetic factors. J Clin Endocrinol Metab 86: 2009–2014.
7. Perry R, Heinrichs C, Bourdoux P, Khoury K, Sotir F, et al. (2002) Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology. J Clin Endocrinol Metab 87: 4072–4077.
8. Devo H, Redd C, Gagne N, Laramee R, Van Vliet G (1999) A search for the possible molecular mechanism of thyroid dysgenesis: sex ratios and associated malformations. J Clin Endocrinol Metab 84: 2502–2506.
9. Deladroue JI, Belanger N, Van Vliet G (2007) Random Variability in Congenital Hypothyroidism from Thyroid Dysgenesis over 16 Years in Quebec. J Clin Endocrinol Metab 92: 3158–3161.
10. Castanet M, Suru-Truhas S, Chausy A, Carre A, de Roux N, et al. (2005) Linkage and mutational analysis of familial thyroid dysgenesis demonstrate genetic heterogeneity implicating novel genes. Eur J Hum Genet 13: 232–239.
11. Deladroue JI, Vassart G, Van Vliet G (2007) Possible non-mendelian mechanisms of thyroid dysgenesis. Endocrinol Dev 10: 29–42.
12. Adler AS, Lin M, Horlings H, Nyten DS, van de Vijver MJ, et al. (2006) Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38: 421–430.
13. Sasaki H, Yoshimoto M, Chalkton-MacNeill S, Thoner P, Squire JA, et al. (2009) Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 18: 1962–1975.
14. Dumont JE (1971) The action of thyrotropin on thyroid metabolism. Vitam Horm 29: 287–412.
15. Bruno R, Ferrari E, Tosi E, Arturi F, Giannasio P, et al. (2005) Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 90: 5692–5697.
16. De Felice M, Di Lauro R (2004) Thyroid Development and Its Disorders: Genetics and Molecular Mechanisms. Endocr Rev 25: 722–746.
17. Angers S, Moon RT (2009) Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468–477.
18. Helvatz A, Van Sande J, Roger PP, Patey M, Klein M, et al. (2009) Thyroid gene expression in familial nonautoimmune hyperthyroidism shows common characteristics with hyperfunctioning autonomous nodules. J Clin Endocrinol Metab 94: 1607–1609.
19. Petrie RJ, Boyle AD, Yamada KM (2009) Random versus directionally persistent cell migration. Nat Rev Mol Cell Biol 10: 538–549.
20. Grigoryan T, Wend P, Klaus A, Birchmeier W (2008) Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 22: 2368–2411.
21. Fagman H, Grande M, Edsbagge J, Semb H, Nilsson M (2003) Expression of classical cadherins in thyroid development: maintenance of an epithelial phenotype throughout organogenesis. Endocrinology 144: 3618–3624.
22. Ebertart CG, Argani P (2001) Wnt signaling in human development: beta-catenin nuclear translocation in fetal lung, kidney, placenta, capillaries, adrenal, and cartilage. Pediatr Dev Pathol 4: 351–357.
23. Nasse R (2003) Wnt signaling in disease and in development. Cell Res 15: 28–32.
24. Satoh W, Gotoh T, Tsunematsu Y, Aizawa S, Shimono A (2006) Sfrp1 and Sfrp2 regulate anteroposterior axis elongation and somite segmentation during mouse embryosgenesis. Development 133: 989–999.
25. Kongkham PN, Northcott PA, Croul SE, Smith CA, Taylor MD, et al. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 29: 3017–3024.
26. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, et al. (2000) Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 19: 498–505.
27. Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T, et al. (2005) Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144–2154.
28. Yang VH, Dudoit S, Loo P, Lin DM, Peng V, et al. (2002) Normalization for multiple slide systematic variation. Nucleic Acids Res 30: e15.
29. Yang VH, Dudoit S, Loo P, Lin DM, Peng V, et al. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15.
30. Team RDC (2006) R: A language and environment for statistical computing; Vienna, Austria.
31. Weber M, Davies JJ, Wittig D, Oakesley EJ, Haase M, et al. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 851–862.
32. Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, et al. (2008) New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal 1: ra12.

Acknowledgments
We thank Drs N. Alos, C. Huot, A. Lapointe (CHU Sainte-Justine, University of Montreal) and H. Bui (Montreal Children Hospital, McGill University) for patient care and provision of samples. We thank Drs C. Deal and G. Van Vliet (CHU Sainte-Justine, University of Montreal) for their continuous support during this project. We thank Dr. Mark E. Samuels (CHU Sainte-Justine, University of Montreal) for reviewing the manuscript.

Author Contributions
Conceived and designed the experiments: GV JD. Performed the experiments: RAK JP AI. FL JD. Analyzed the data: RAK JP AI FL JPC GV JD. Contributed reagents/materials/analysis tools: JP AI FL JPC GV JD. Wrote the paper: RAK JP AI FL JPC GV JD.